Analyst Consensus ?
ConsensusBuy42 ratings
Bullish3583.3%
Neutral716.7%
Bearish00.0%
FN2 Earnings Intelligence
Thermo Fisher Scientific Inc. complete analyst coverage
Thermo Fisher Scientific Inc. (TMO) analyst consensus, price targets, and firm-level rating history from FN2 Research.
Analyst 52W Price Targets
$684.89Current
$460Low
$654.77Average
$800High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 27, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Citigroup | Buy | Buy | Maintain | Oct 23, 2026 |
| TD Cowen | Buy | Buy | Maintain | Oct 22, 2026 |
| Stifel | Buy | Buy | Maintain | Oct 22, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Oct 22, 2026 |
| Barclays | Overweight | Overweight | Maintain | Oct 22, 2026 |
| Baird | Outperform | Outperform | Maintain | Oct 22, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Oct 13, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Jul 27, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 6, 2026 |
| HSBC | Hold | Buy | Downgrade | Jun 3, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | May 8, 2026 |
| Keybanc | Overweight | Sector Weight | Upgrade | Dec 8, 2025 |
| Argus Research | Buy | Buy | Maintain | Oct 29, 2025 |
| UBS | Neutral | Neutral | Maintain | Oct 23, 2025 |
| Leerink Partners | Outperform | Outperform | Maintain | Oct 22, 2025 |
| JP Morgan | Overweight | Overweight | Maintain | Oct 9, 2025 |
| Raymond James | Outperform | Outperform | Maintain | Jul 24, 2025 |
| Scotiabank | Sector Outperform | Sector Perform | Upgrade | Jul 11, 2025 |
| B of A Securities | Buy | Buy | Maintain | Dec 13, 2024 |
| Bernstein | Market Perform | Market Perform | Maintain | Oct 24, 2024 |
| Deutsche Bank | Buy | Buy | Maintain | Apr 25, 2024 |
| Goldman Sachs | Buy | Buy | Maintain | Apr 10, 2024 |
| Credit Suisse | Outperform | Neutral | Upgrade | Jul 13, 2023 |
| SVB Leerink | Outperform | Outperform | Maintain | Jul 6, 2023 |
| Cowen & Co. | Outperform | Outperform | Maintain | Feb 2, 2023 |
| BTIG | Buy | Buy | Maintain | Feb 2, 2022 |
| Benchmark | Buy | Buy | Maintain | Jul 16, 2021 |
| Needham | Buy | Buy | Maintain | Dec 1, 2020 |
| Atlantic Equities | Overweight | Overweight | Maintain | Sep 30, 2020 |
| Cleveland Research | Buy | Neutral | Upgrade | Jul 15, 2020 |
| Stifel Nicolaus | Buy | Buy | Maintain | Nov 15, 2019 |
| Bank of America | Buy | Buy | Maintain | Feb 1, 2018 |
| BTIG Research | Buy | Buy | Maintain | Jan 5, 2018 |
| Leerink Swann | Outperform | Outperform | Maintain | Oct 9, 2017 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | May 19, 2017 |
| Jefferies | Hold | Buy | Downgrade | Apr 29, 2016 |
| Avondale Partners | Outperform | Market Outperform | Maintain | Jan 6, 2016 |
| Macquarie | Outperform | Outperform | Maintain | Jul 24, 2014 |
| Janney Capital | Buy | Buy | Maintain | Aug 15, 2013 |
| ISI Group | Buy | Buy | Maintain | Jan 31, 2013 |
| Wallachbeth | Buy | Buy | Maintain | Aug 9, 2012 |
| Mizuho | Neutral | Buy | Downgrade | May 15, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $684.89. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Douglas Schenkel | $800 | $686.55 | +16.8% | Oct 22, 2026 |
| RBC Capital | Dan Leonard | $730 | $687.49 | +6.6% | Oct 22, 2026 |
| Stifel Nicolaus | Analyst unavailable | $775 | $694.02 | +13.2% | Oct 22, 2026 |
| Robert W. Baird | Analyst unavailable | $756 | $694.02 | +10.4% | Oct 22, 2026 |
| Barclays | Luke Sergott | $775 | $694.02 | +13.2% | Oct 22, 2026 |
| RBC Capital | Analyst unavailable | $740 | $673.2 | +8.0% | Oct 15, 2026 |
| Guggenheim | Analyst unavailable | $740 | $673.2 | +8.0% | Oct 15, 2026 |
| Morgan Stanley | Analyst unavailable | $730 | $659.6 | +6.6% | Oct 12, 2026 |
| Barclays | Luke Sergott | $750 | $656.58 | +9.5% | Oct 7, 2026 |
| Deutsche Bank | Analyst unavailable | $720 | $665.25 | +5.1% | Sep 25, 2026 |
| UBS | Analyst unavailable | $730 | $603.02 | +6.6% | Sep 8, 2026 |
| CLSA | Michael Luo | $748 | $608.54 | +9.2% | Sep 3, 2026 |
| Stifel Nicolaus | Analyst unavailable | $650 | $564.75 | -5.1% | Aug 5, 2026 |
| Piper Sandler | Analyst unavailable | $600 | $568.26 | -12.4% | Jul 27, 2026 |
| Morgan Stanley | Analyst unavailable | $650 | $568.26 | -5.1% | Jul 24, 2026 |
| RBC Capital | Dan Leonard | $580 | $561.09 | -15.3% | Jul 24, 2026 |
| Jefferies | Tycho Peterson | $630 | $572.6 | -8.0% | Jul 23, 2026 |
| Evercore ISI | Analyst unavailable | $570 | $511.31 | -16.8% | Jul 6, 2026 |
| Bernstein | Analyst unavailable | $520 | $505.75 | -24.1% | Jun 26, 2026 |
| Piper Sandler | Analyst unavailable | $510 | $482.04 | -25.5% | Jun 11, 2026 |
| HSBC | Sidharth Sahoo | $540 | $482.08 | -21.2% | Jun 3, 2026 |
| RBC Capital | Analyst unavailable | $490 | $448.21 | -28.5% | May 14, 2026 |
| Morgan Stanley | Kallum Titchmarsh | $620 | $472.23 | -9.5% | Apr 27, 2026 |
| Stifel Nicolaus | Daniel Arias | $600 | $467.47 | -12.4% | Apr 24, 2026 |
| Robert W. Baird | Catherine Ramsey Schulte | $639 | $466.7 | -6.7% | Apr 24, 2026 |
| UBS | Analyst unavailable | $615 | $579.86 | -10.2% | Jan 30, 2026 |
| Wells Fargo | Analyst unavailable | $683 | $580.09 | -0.3% | Jan 30, 2026 |
| Robert W. Baird | Analyst unavailable | $653 | $583.12 | -4.7% | Jan 30, 2026 |
| Barclays | Analyst unavailable | $650 | $592.16 | -5.1% | Jan 30, 2026 |
| Stifel Nicolaus | Daniel Arias | $700 | $606.5 | +2.2% | Jan 9, 2026 |
| Evercore ISI | Vijay Kumar | $650 | $605.83 | -5.1% | Jan 5, 2026 |
| Wells Fargo | Analyst unavailable | $675 | $571.99 | -1.4% | Dec 15, 2025 |
| Goldman Sachs | Evie Koslosky | $685 | $568.21 | +0.0% | Dec 9, 2025 |
| KeyBanc | Paul Knight | $750 | $572.77 | +9.5% | Dec 7, 2025 |
| Argus Research | Analyst unavailable | $610 | $570.82 | -10.9% | Oct 29, 2025 |
| Morgan Stanley | Analyst unavailable | $656 | $563.28 | -4.2% | Oct 28, 2025 |
| UBS | Analyst unavailable | $590 | $571.68 | -13.9% | Oct 23, 2025 |
| Barclays | Analyst unavailable | $625 | $567.2 | -8.7% | Oct 23, 2025 |
| Leerink Partners | Analyst unavailable | $580 | $567.2 | -15.3% | Oct 22, 2025 |
| Redburn Partners | Analyst unavailable | $575 | $536.19 | -16.0% | Oct 8, 2025 |
| Redburn Partners | Analyst unavailable | $580 | $539.17 | -15.3% | Oct 8, 2025 |
| Barclays | Luke Sergott | $585 | $530.73 | -14.6% | Oct 2, 2025 |
| RBC Capital | Conor McNamara | $561 | $487.53 | -18.1% | Sep 2, 2025 |
| UBS | Dan Leonard | $460 | $426.17 | -32.8% | Jul 8, 2025 |
| Scotiabank | Analyst unavailable | $605 | $424.24 | -11.7% | Apr 25, 2025 |
| Goldman Sachs | Matthew Sykes | $610 | $431.64 | -10.9% | Apr 23, 2025 |
| RBC Capital | Conor McNamara | $693 | $597.75 | +1.2% | Jan 31, 2025 |
| Evercore ISI | Vijay Kumar | $585 | $522.57 | -14.6% | Jan 2, 2025 |
| Robert W. Baird | Catherine Schulte | $622 | $576.49 | -9.2% | Oct 24, 2024 |
| Barclays | Luke Sergott | $610 | $570.92 | -10.9% | Oct 23, 2024 |
| Evercore ISI | Vijay Kumar | $630 | $618.57 | -8.0% | Oct 1, 2024 |
| Stifel Nicolaus | Daniel Arias | $680 | $620.25 | -0.7% | Sep 20, 2024 |
| Robert W. Baird | Catherine Schulte | $632 | $620.25 | -7.7% | Sep 20, 2024 |
| Citigroup | Patrick Donnelly | $620 | $617.1 | -9.5% | Sep 19, 2024 |
| Deutsche Bank | Justin Bowers | $630 | $609.41 | -8.0% | Sep 18, 2024 |
| Bank of America Securities | Derik de Bruin | $675 | $611.17 | -1.4% | Sep 16, 2024 |
| Raymond James | Andrew Cooper | $660 | $593.86 | -3.6% | Jul 25, 2024 |
| Barclays | Luke Sergott | $600 | $550.78 | -12.4% | Jun 28, 2024 |
| HSBC | Sidharth Sahoo | $670 | $576.89 | -2.2% | Apr 30, 2024 |
| Deutsche Bank | Justin Bowers | $610 | $577.39 | -10.9% | Apr 25, 2024 |
| Barclays | Luke Sergott | $615 | $577.39 | -10.2% | Apr 25, 2024 |
| Robert W. Baird | Catherine Schulte | $670 | $531.65 | -2.2% | Dec 28, 2023 |
| Raymond James | Andrew Cooper | $530 | $444.46 | -22.6% | Oct 26, 2023 |
| Credit Suisse | Thermo Fisher | $620 | $525.63 | -9.5% | Jul 13, 2023 |
| Cowen & Co. | Analyst unavailable | $711 | $591.95 | +3.8% | Feb 2, 2023 |
| Citigroup | Analyst unavailable | $700 | $589.73 | +2.2% | Feb 2, 2023 |
| Barclays | Analyst unavailable | $660 | $587.36 | -3.6% | Feb 2, 2023 |
| Leerink Partners | Analyst unavailable | $630 | $587.36 | -8.0% | Feb 2, 2023 |
| Leerink Partners | Analyst unavailable | $620 | $532.88 | -9.5% | Jan 6, 2023 |
| Wells Fargo | Analyst unavailable | $505 | $553.18 | -26.3% | Jan 3, 2023 |
| Deutsche Bank | Analyst unavailable | $620 | $571.38 | -9.5% | Dec 14, 2022 |
| RBC Capital | Analyst unavailable | $661 | $550.53 | -3.5% | Dec 7, 2022 |
| Barclays | Analyst unavailable | $570 | $540.03 | -16.8% | Nov 29, 2022 |
| Barclays | Analyst unavailable | $595 | $569.4 | -13.1% | Sep 12, 2022 |
| Barclays | Luke Sergott | $685 | $587.98 | +0.0% | Aug 4, 2022 |
| Morgan Stanley | Analyst unavailable | $678 | $606.24 | -1.0% | Jul 29, 2022 |
| Leerink Partners | Analyst unavailable | $650 | $597.64 | -5.1% | Jul 29, 2022 |
| Barclays | Analyst unavailable | $630 | $530.93 | -8.0% | Jul 13, 2022 |
| Morgan Stanley | Analyst unavailable | $670 | $563.79 | -2.2% | Apr 29, 2022 |
| Wells Fargo | Analyst unavailable | $525 | $561.28 | -23.3% | Apr 25, 2022 |
| Morgan Stanley | Tejas Savant | $700 | $619.47 | +2.2% | Oct 28, 2021 |
| Benchmark Co. | Robert Wasserman | $650 | $611.7 | -5.1% | Oct 27, 2021 |
| Goldman Sachs | Matthew Sykes | $690 | $607.64 | +0.7% | Sep 23, 2021 |
| J.P. Morgan | Tycho Peterson | $700 | $589.63 | +2.2% | Sep 20, 2021 |
| Bank of America Securities | Derik De Bruin | $670 | $589.63 | -2.2% | Sep 20, 2021 |
| KeyBanc | Paul Knight | $710 | $589.63 | +3.7% | Sep 20, 2021 |
| Jefferies | Brandon Couillard | $540 | $589.63 | -21.2% | Sep 20, 2021 |
| Argus Research | David Toung | $600 | $538.11 | -12.4% | Aug 4, 2021 |
Track every rating change on TMO the moment it posts. Free to start.
Start freeGet the TMO recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.